evacetrapib + warfarin

Evacetrapib + warfarin is a combination of two small molecule drugs. **Evacetrapib** is a cholesteryl ester transfer protein (CETP) inhibitor developed to reduce cardiovascular events by raising HDL cholesterol and lowering LDL cholesterol[1][2][3]. **Warfarin** is a vitamin K antagonist anticoagulant, inhibiting the synthesis of vitamin K-dependent clotting factors, widely used for preventing and treating thromboembolic disorders. The combination is primarily of interest for its potential drug–drug interactions, as patients taking evacetrapib for cardiovascular risk reduction may also require anticoagulation with warfarin. Evidence to date suggests that evacetrapib has minimal clinically relevant CYP-mediated drug–drug interactions, including with CYP2C9 substrates such as warfarin[1][3].